Published in Hum Mol Genet on March 26, 2011
Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy. Am J Pathol (2012) 1.02
The dystrophin-glycoprotein complex in the prevention of muscle damage. J Biomed Biotechnol (2011) 0.97
Laminin-111 improves muscle repair in a mouse model of merosin-deficient congenital muscular dystrophy. Hum Mol Genet (2013) 0.86
Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A). Skelet Muscle (2012) 0.86
Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice. Mol Ther (2014) 0.82
Inhibition of extracellular signal-regulated kinase 1/2 signaling has beneficial effects on skeletal muscle in a mouse model of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene mutation. Skelet Muscle (2013) 0.82
Dysregulation of matricellular proteins is an early signature of pathology in laminin-deficient muscular dystrophy. Skelet Muscle (2014) 0.82
Quantitative proteomic analysis reveals metabolic alterations, calcium dysregulation, and increased expression of extracellular matrix proteins in laminin α2 chain-deficient muscle. Mol Cell Proteomics (2014) 0.79
miR-410 and miR-495 Are Dynamically Regulated in Diverse Cardiomyopathies and Their Inhibition Attenuates Pathological Hypertrophy. PLoS One (2016) 0.75
Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A). PLoS One (2015) 0.75
Combining immunodetection with histochemical techniques: the effect of heat-induced antigen retrieval on picro-Sirius red staining. J Histochem Cytochem (2014) 0.75
Absence of microRNA-21 does not reduce muscular dystrophy in mouse models of LAMA2-CMD. PLoS One (2017) 0.75
Identification of ubiquitin ligases required for skeletal muscle atrophy. Science (2001) 12.98
Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell (2004) 11.33
Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol (2001) 10.85
Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol (2001) 6.71
Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet (2001) 5.18
The insulin-like growth factor system and cancer. Cancer Lett (2003) 4.91
Form and function: the laminin family of heterotrimers. Dev Dyn (2000) 4.38
Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev (1996) 3.26
The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem (1997) 3.05
Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol (2002) 2.76
Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol (1984) 2.66
Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol (2005) 2.61
Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul Disord (2004) 2.37
The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol (2003) 2.36
Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron (2009) 2.26
Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. Neuromuscul Disord (2001) 1.97
Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet (1999) 1.93
Contribution of satellite cells to IGF-I induced hypertrophy of skeletal muscle. Acta Physiol Scand (1999) 1.72
Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy. FEBS Lett (1997) 1.67
Proliferation precedes differentiation in IGF-I-stimulated myogenesis. J Cell Biol (1996) 1.67
An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature (2001) 1.65
The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscul Disord (2004) 1.63
Satellite cell proliferation and the expression of myogenin and desmin in regenerating skeletal muscle: evidence for two different populations of satellite cells. Lab Invest (1995) 1.62
ERK1/2 is required for myoblast proliferation but is dispensable for muscle gene expression and cell fusion. J Cell Physiol (2001) 1.60
Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J Appl Physiol (1985) (1998) 1.59
Age-related changes in replication of myogenic cells in mdx mice: quantitative autoradiographic studies. J Neurol Sci (1993) 1.47
Do immune cells promote the pathology of dystrophin-deficient myopathies? Neuromuscul Disord (2001) 1.43
Merosin and laminin in myogenesis; specific requirement for merosin in myotube stability and survival. J Cell Biol (1996) 1.42
Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy. J Clin Invest (2004) 1.41
Laminin alpha1 chain reduces muscular dystrophy in laminin alpha2 chain deficient mice. Hum Mol Genet (2004) 1.29
IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice. Neuromuscul Disord (2001) 1.29
Muscle-specific BCL2 expression ameliorates muscle disease in laminin {alpha}2-deficient, but not in dystrophin-deficient, mice. Hum Mol Genet (2005) 1.28
Activation of the lama2 gene in muscle regeneration: abortive regeneration in laminin alpha2-deficiency. Lab Invest (1999) 1.26
Phosphoinositide 3-kinase induces the transcriptional activity of MEF2 proteins during muscle differentiation. J Biol Chem (2000) 1.26
Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha2-deficient mice. FASEB J (2005) 1.18
Inhibition of dystroglycan binding to laminin disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve (2002) 1.17
Increased protein synthesis after acute IGF-I or insulin infusion is localized to muscle in mice. Am J Physiol (1998) 1.17
Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy. Neuromuscul Disord (2001) 1.16
Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stages. J Cell Biol (2007) 1.15
Insulin-like growth factor 1 and muscle growth: implication for satellite cell proliferation. Proc Nutr Soc (2004) 1.14
Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology (2003) 1.10
Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy. Ann Neurol (2009) 1.09
Targeted expression of insulin-like growth factor-I reduces early myofiber necrosis in dystrophic mdx mice. Mol Ther (2004) 1.08
Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-alpha2 deficiency. J Pharmacol Exp Ther (2009) 1.06
Forkhead transcription factor FoxO1 transduces insulin-like growth factor's signal to p27Kip1 in primary skeletal muscle satellite cells. J Cell Physiol (2003) 1.01
Expression of mouse agrin in normal, denervated and dystrophic muscle. Neuromuscul Disord (2003) 1.01
Dystrophin glycoprotein complex-associated Gbetagamma subunits activate phosphatidylinositol-3-kinase/Akt signaling in skeletal muscle in a laminin-dependent manner. J Cell Physiol (2009) 1.00
Laminin alpha1 chain improves laminin alpha2 chain deficient peripheral neuropathy. Hum Mol Genet (2006) 0.98
Laminin alpha1 chain mediated reduction of laminin alpha2 chain deficient muscular dystrophy involves integrin alpha7beta1 and dystroglycan. FEBS Lett (2006) 0.97
Transgenic overexpression of laminin alpha1 chain in laminin alpha2 chain-deficient mice rescues the disease throughout the lifespan. Muscle Nerve (2010) 0.97
Distinct roles for laminin globular domains in laminin alpha1 chain mediated rescue of murine laminin alpha2 chain deficiency. PLoS One (2010) 0.96
cDNA microarray analysis of individual Duchenne muscular dystrophy patients. Hum Mol Genet (2003) 0.96
Feeding problems in merosin deficient congenital muscular dystrophy. Arch Dis Child (1999) 0.91
Loss of muscle strength during aging studied at the gene level. Rejuvenation Res (2007) 0.88
Merosin-integrin promotion of skeletal myofiber cell survival: Differentiation state-distinct involvement of p60Fyn tyrosine kinase and p38alpha stress-activated MAP kinase. J Cell Physiol (2002) 0.88
Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage. Exp Physiol (2008) 0.87
Diseased muscles that lack dystrophin or laminin-alpha2 have altered compositions and proliferation of mononuclear cell populations. BMC Neurol (2005) 0.83
Expression profiling of muscles from Fukuyama-type congenital muscular dystrophy and laminin-alpha 2 deficient congenital muscular dystrophy; is congenital muscular dystrophy a primary fibrotic disease? Biochem Biophys Res Commun (2006) 0.83
Regenerative capacity of mdx mouse muscles after repeated applications of myo-necrotic bupivacaine. Acta Neuropathol (1995) 0.83
98th ENMC International Workshop on Congenital Muscular Dystrophy (CMD), 7th Workshop of the International Consortium on CMD, 2nd Workshop of the MYO CLUSTER project GENRE. 26-28th October, 2001, Naarden, The Netherlands. Neuromuscul Disord (2002) 0.82
The role of apoptosis in neuromuscular diseases and prospects for anti-apoptosis therapy. Trends Mol Med (2006) 0.94
Immortalization of mouse myogenic cells can occur without loss of p16INK4a, p19ARF, or p53 and is accelerated by inactivation of Bax. BMC Cell Biol (2004) 0.89
Dysregulation of matricellular proteins is an early signature of pathology in laminin-deficient muscular dystrophy. Skelet Muscle (2014) 0.82
Prdm1 (Blimp-1) and the expression of fast and slow myosin heavy chain isoforms during avian myogenesis in vitro. PLoS One (2010) 0.82
Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1 A. Hum Mol Genet (2013) 0.79
IGF-1/GH axis enhances losartan treatment in Lama2-related muscular dystrophy. Hum Mol Genet (2016) 0.77
Report on the Myomatrix Conference April 22-24, 2012, University of Nevada, Reno, Nevada, USA. Neuromuscul Disord (2012) 0.76